Paying users zone. Data is hidden behind: .
Get 1-month access to Amgen Inc. for $17.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Analysis of Revenues
Revenues as Reported
Amgen Inc., Income Statement, Revenues
US$ in millions
| 12 months ended: | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Human therapeutics | |||||||||||
| Product sales | |||||||||||
| Other revenues | |||||||||||
| Revenues |
Based on: 10-K (filing date: 2021-02-09), 10-K (filing date: 2020-02-12), 10-K (filing date: 2019-02-13), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-14).
| Item | Description | The company |
|---|---|---|
| Revenues | Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). | Amgen Inc.’s revenues decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level. |